Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;51(10):904-910.
doi: 10.1111/jop.13354. Epub 2022 Sep 20.

Angiosarcomas of the head and neck: Impact of large data analysis on clinical management

Volkert B Wreesmann  1   2   3 , Karin P Oomen  3 , Peter A Brennan  4
Affiliations
Review

Angiosarcomas of the head and neck: Impact of large data analysis on clinical management

Volkert B Wreesmann et al. J Oral Pathol Med. 2022 Nov.

Abstract

Angiosarcoma is a rare but often fatal malignancy from blood and lymphatic vessels that can arise anywhere in the body and often affects the head and neck region. Although its dismal prognosis is predominantly explained by its aggressive biology, several secondary factors contribute to poor outcomes. These include a phenotypic resemblance to innocuous blood vessel lesions, which contributes to a significant degree of late diagnosis. Another important factor is the rarity of angiosarcoma, which has impaired scientific determination of its optimal treatment significantly. As a result, treatment of angiosarcomas has largely been guided by information derived from the study of sarcomas at large, themselves a highly heterogeneous group of mesenchymal cancers both from a diagnostic as well as therapeutical perspective. The Digital Revolution and resultant Information Age promise to transform the clinical management of rare cancers from a generic to a more customized approach. In this paper, we review the current understanding of head and neck angiosarcomas within the context of this process.

Keywords: angiosarcoma; head and neck; outcomes; review.

PubMed Disclaimer

References

REFERENCES

    1. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010;11(10):983-991. doi:10.1016/S1470-2045(10)70023-1
    1. O'Neill JP, Bilsky MH, Kraus D. Head and neck sarcomas: epidemiology, pathology, and management. Neurosurg Clin N Am. 2013;24(1):67-78. doi:10.1016/j.nec.2012.08.010
    1. Behjati S, Tarpey PS, Sheldon H, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet. 2014;46(4):376-379. doi:10.1038/ng.2921
    1. Resteghini C, Trama A, Borgonovi E, et al. Big data in head and neck cancer. Curr Treat Options Oncol. 2018;19(12):62. doi:10.1007/s11864-018-0585-2
    1. Conic RRZ, Damiani G, Frigerio A, et al. Incidence and outcomes of cutaneous angiosarcoma: a SEER population-based study. J Am Acad Dermatol. 2020;83(3):809-816. doi:10.1016/j.jaad.2019.07.024